Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Current Assets (2017 - 2025)

Sutro Biopharma's Current Assets history spans 9 years, with the latest figure at $182.1 million for Q3 2025.

  • For Q3 2025, Current Assets fell 55.12% year-over-year to $182.1 million; the TTM value through Sep 2025 reached $182.1 million, down 55.12%, while the annual FY2024 figure was $343.3 million, 18.56% down from the prior year.
  • Current Assets for Q3 2025 was $182.1 million at Sutro Biopharma, down from $231.6 million in the prior quarter.
  • Across five years, Current Assets topped out at $443.5 million in Q2 2024 and bottomed at $182.1 million in Q3 2025.
  • The 5-year median for Current Assets is $331.5 million (2022), against an average of $317.9 million.
  • The largest annual shift saw Current Assets surged 108.7% in 2021 before it crashed 55.12% in 2025.
  • A 5-year view of Current Assets shows it stood at $218.5 million in 2021, then skyrocketed by 61.61% to $353.2 million in 2022, then grew by 19.37% to $421.5 million in 2023, then decreased by 18.56% to $343.3 million in 2024, then plummeted by 46.95% to $182.1 million in 2025.
  • Per Business Quant, the three most recent readings for STRO's Current Assets are $182.1 million (Q3 2025), $231.6 million (Q2 2025), and $287.4 million (Q1 2025).